Bipolar depression: An evidence-based approach

Current Psychiatry Reports

Volumn 13, Issue 6, 2011, Pages 483-487

  Baldassano, Claudia F ^a   Hosey, Alexander ^a   Coello, Jordan ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antidepressants; Bipolar depression; Evidence based medicine; Mood stabilizers; Pharmacotherapy; Research; Treatment guidelines

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; FLUOXETINE; ILOPERIDONE; IMIPRAMINE; INOSITOL; LAMOTRIGINE; LITHIUM SALT; LURASIDONE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; TRANQUILIZER;

ACNE; ADD ON THERAPY; AKATHISIA; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOMANIA; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; MENTAL INSTABILITY; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; POLYDIPSIA; POLYURIA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SEDATION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; BIPOLAR DISORDER; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84855866579     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-011-0238-7     Document Type: Article

References (47)

1. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health. 2010;13(8):984-8.
2. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9(5):531-5. (Pubitemid 47202517)
3. Osby Y, Brandt L, Coreia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psych. 2001;58(9):844-50. (Pubitemid 32979302)
4. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841-50.
5. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: Beyond DSM-IV. J Clin Psychopharmacol. 1996;16 Suppl 1:4-14.
6. Thase ME, Sachs GS. Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biol Psychiatry. 2000;48:558-72.
7. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: Polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175-83.
8. Calabrese JR, Rapport DJ, Shelton MD, Kimmel S. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology. 1998;38:185-91. (Pubitemid 28479455)
9. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry. 2001;62:565-9. (Pubitemid 32703099)
10. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-22. (Pubitemid 46658703)
11. Post RM, Leverich GS, Nolen WA, Kupka RW, Altshuler LL, Frye MA, et al. Stanley foundation bipolar network. A reevaluation of the role of antidepressants in the treatment of bipolar depression: Data from the Stanley Foundation Bipolar Network. Bipolar Disord. 2003;5(6):396-406. (Pubitemid 38072242)
12. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163-74.
13. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161 (9):1537-47. (Pubitemid 39201448)
14. Strejilevich SA, Martino DJ, Marengo E, Igoa A, Fassi G, Whitham EA, Ghaemi SN. Long-term worsening of bipolar disorder related with frequency of antidepressant exposure. Ann Clin Psychiatry. 2011;23(3):186-92. This study was important in that it evaluated the long-term effects of antidepressants on bipolar illness.
15. Zornberg GL, Pope Jr. HG. treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol. 1993;13:397-408. (Pubitemid 24026101)
16. Strakowski SM, McElroy SL, Keck PE. Clinical efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium. In: Halbreich U, Montgomery SA, editors. Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press; 2000. p. 143-57.
17. Goodwin FK, Jamison KR. Maniccbdepressive illness. New York: Oxford University Press; 1990.
18. Goodwin FK, Murphy DL, Bunney Jr. WF. Lithium carbonate treatment in depression and mania: A longitudinal double-blind study. Arch Gen Psychiatry. 1969;21:486-96.
19. Goodwin FK, Murphy DL, Dunner DL, Bunney Jr. WF. Lithium response in unipolar versus bipolar depression. Am J Psychiatry. 1972;129:44-7.
20. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-12. (Pubitemid 32547620)
21. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: Observational nationwide register-based cohort study. Br J Psychiatry. 2011;199:57-63. This study compared two older agents that are widely used in bipolar disorder and showed the evidence supporting the use of lithium.
22. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467-73. (Pubitemid 37430401)
23. Søndergård L, Lopez AG, Andersen PK, Kessing LV. Moodstabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008;10(1):87-94.
24. Grunze HC. Anticonvulsants in bipolar disorder. J Ment Health. 2010;19(2):127-41.
25. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4-9.
26. van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-31. Epub 2008 Dec 30.
27. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 May 3. doi:10.4088/JCP. 09m05934.
28. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13-20.
29. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-9. (Pubitemid 44772737)
30. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: A randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007;9 (4):413-25. (Pubitemid 46865372)
31. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. EMBOLDEN I (Trial 001) investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatr. 2010;71(2):150-62.
32. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Bipolar Disord. 2007;9(4):413-25.
33. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: Secondary analyses of a double-blind, placebocontrolled, randomized clinical. Clin Ther. 2004;26(1):125-34. (Pubitemid 38241530)
34. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7:239-50.
35. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673-86.
36. Yasui-Furukori N, Saito M, Nakagami T, Furukori H, Suzuki A, Kondo T, et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol. 2010;24(7):987-94.
37. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatmentresistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol and risperidone. Am J Psychiatr. 2006;163:210-6. (Pubitemid 44480839)
38. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: A failed but clinically useful study. Acta Psychiatr Scand. 2007;115:360-5. (Pubitemid 46570066)
39. Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT. 2003;19(1):10-6. (Pubitemid 36298275)
40. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression (letter). Am J Psychiatr. 1999;156:798. (Pubitemid 29220089)
41. Zarate Jr. CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Biol Psychiatr. 2004;56(1):54-60.
42. Frye MA, Grunze H, Suppes T,McElroy SL, Keck Jr. PE,Walden J, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatr. 2007;164(8):1242-9. (Pubitemid 47292414)
43. Depakote Product Information. Physicians' desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.
44. Esaklith Product Information. Physicians' desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.
45. Tegretol Product Information. Physicians' desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.
46. Lamictal Product Information. Physicians' desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.
47. Zyprexa Product Information. Physicians' desk reference electronic library. 56th ed. Montvale: Medical Economics Company, Inc; 2002.